AYALA PHARMACEUTICALS INC - ADXS STOCK NEWS

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotech firm, will have its CEO, Kenneth A. Berlin, present at the Benzinga Biotech Small Cap Conference on March 24-25, 2021. Berlin's presentation is scheduled for 2:30 PM ET on March 24. Interested investors can view the presentation and request meetings via registration at the conference's website. Advaxis specializes in immunotherapy products utilizing bioengineered Listeria monocytogenes for enhanced anti-tumor T-cell immunity. For more details, visit advaxis.com.

Advaxis, Inc. (Nasdaq: ADXS) reported promising results from its ongoing Phase 1/2 trial of ADXS-503 in non-small cell lung cancer (NSCLC), with a disease control rate of 67% and an overall response rate of 17% among the first six patients who had prior progression on KEYTRUDA®. The company recently closed a $9.2 million public offering, strengthening its balance sheet to support continued clinical development. Research and development expenses were reduced to $2.6 million, allowing the company to maintain a solid cash position of $33.3 million through May 2022.

Advaxis (Nasdaq: ADXS) announced a collaboration with Precision for Medicine to present data at the AACR Annual Meeting 2021, scheduled from April 10-15. The presentation will focus on a novel flow immunophenotyping assay for evaluating PD-1 expression during pembrolizumab treatment and its correlation with T cell populations in the ongoing ADXS-503 trial. The poster, titled Evaluation of total PD-1 expression using multi-color flow cytometry, highlights immunotherapy advancements in metastatic non-small cell lung cancer. Full details will be available on the AACR website starting April 10.

Advaxis, a biotechnology company focused on immunotherapy, is advancing its ADXS-503 program in non-small cell lung cancer (NSCLC). Recent clinical data showed a 67% disease control rate and 17% overall response rate in patients previously treated with KEYTRUDA®. The company strengthened its financial position with a $9.2 million public offering and initiated new clinical arms for ADXS-503. For the fiscal year ending October 31, 2020, Advaxis reported a net loss of $26.5 million and reduced R&D expenses by $11.1 million.

Advaxis, Inc. (NASDAQ: ADXS) announced a milestone payment for its licensing agreement with OS Therapies for ADXS31-164 (OST-HER2) aimed at treating osteosarcoma. OS Therapies, in collaboration with the Children’s Oncology Group, will conduct a clinical study funded through secured financing. Advaxis will receive additional milestone payments and royalties on future sales. The treatment has potential benefits for children with limited options, building on prior successful trials in canines and humans. Advaxis continues to focus on its ADXS-HOT neoantigen program.

Advaxis, Inc. (Nasdaq: ADXS) has received approval to transfer its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective December 24, 2020. This decision follows the company's stock trading below the minimum bid price required. Advaxis has been granted an additional 180-day period to meet the $1.00 bid price requirement, expiring June 21, 2021. If the stock does not regain compliance, it may face delisting, although an appeal option is available. Notably, the company plans to consider a reverse stock split if necessary, to meet the bid price requirement.

Advaxis, Inc. (ADXS) has successfully closed an underwritten public offering of 26,666,666 common shares and warrants for 13,333,333 shares, raising approximately $9.2 million at $0.30 per share. This includes an overallotment of 3,999,999 shares and 1,999,999 warrants. The funds will support ongoing R&D, particularly the ADXS-HOT program, and may also be used for potential acquisitions or investments. The offering was executed under an effective shelf registration statement.

Advaxis, Inc. (Nasdaq: ADXS) has announced a public offering of 26,666,666 shares of common stock and warrants to purchase 13,333,333 shares at $0.30 per unit. The warrants are exercisable at $0.35 each and will expire in five years. The underwriters have a 30-day option to purchase additional shares to cover over-allotments. Proceeds will support R&D initiatives, including the ADXS-HOT program, and may also fund acquisitions of new businesses or technologies. A.G.P./Alliance Global Partners is the book-running manager for this offering.

Advaxis, Inc. (Nasdaq: ADXS) has announced plans for an underwritten public offering of its common stock and warrants to purchase common stock. The company intends to grant underwriters a 30-day option to purchase an additional 15% of the offered shares. Proceeds will support research and development efforts, particularly the ADXS-HOT program, and potential investments in other businesses or technologies. The offering is subject to market conditions, and further details will be provided in a prospectus supplement.